SCHEMBL2017807

SCHEMBL2017807

COc1ccc(C2C(C)C(=O)N2c2cc(OC)c(OC)c(OC)c2)cc1O[Si](C)(C)C(C)(C)C

nearest known ligand 0.50

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ESR1 P03372 3/20 0.43
ESR2 Q92731 2/20 0.43
HDAC1 Q13547 2/20 0.41
HDAC8 Q9BY41 2/20 0.41
HDAC6 Q9UBN7 2/20 0.41
NPSR1 Q6W5P4 2/20 0.38
PDE4A P27815 1/20 0.38
PDE4B Q07343 1/20 0.38
PDE4C Q08493 1/20 0.38
PDE4D Q08499 1/20 0.38
HTR7 P34969 1/20 0.38
SMN1; SMN2 Q16637 1/20 0.37
CA1 P00915 3/20 0.37
CA2 P00918 3/20 0.37
CA4 P22748 3/20 0.37
CA7 P43166 3/20 0.37
TUBB4A P04350 1/20 0.36
TUBB P07437 1/20 0.36
TUBA3C P0DPH7 1/20 0.36
TUBA1B P68363 1/20 0.36

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL20707998 0.85 HIF1A (0.45) NPSR1PDE4APDE4BPDE4CPDE4D
SCHEMBL1996385 0.83 NPSR1 (0.53) ESR1ESR2NPSR1SMN1; SMN2CA1
SCHEMBL2017809 0.82 ESR1 (0.41) ESR1ESR2CA1CA2CA4
SCHEMBL1997707 0.81 HTR7 (0.42) ESR1ESR2NPSR1PDE4APDE4B
SCHEMBL22773172 0.80 HTR7 (0.37) ESR1ESR2HTR7SMN1; SMN2ACHE
SCHEMBL20695904 0.80 HTR7 (0.37) ESR1ESR2HTR7SMN1; SMN2ACHE
SCHEMBL19423013 0.80 HTR7 (0.37) ESR1ESR2HTR7SMN1; SMN2ACHE
SCHEMBL30479084 0.80 HTR7 (0.37) ESR1ESR2HTR7SMN1; SMN2ACHE
SCHEMBL20707980 0.79 ESR1 (0.48) ESR1ESR2HDAC1HDAC8HDAC6
SCHEMBL24167885 0.78 HDAC1 (0.57) ESR1ESR2HDAC1HDAC8HDAC6

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20120309734-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2012-12-06 US disclosed
EP-2513051-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR The Provost, Fellows, Foundation Scholars, & the other members of Board, of the College of the Holy & Undiv. Trinity of Queen Elizabeth near Dublin (IE) 2012-10-24 EP disclosed
WO-2011073211-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR THE PROVOST, FELLOWS AND SCHOLARS OF THE COLLEGE OF THE HOLY AND UNDIVIDED TRINITY OF QUEEN ELIZABETH, NEAR DUBLIN (IE) 2011-06-23 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120309734-A1 COMBRETASTATIN DERIVATIVES AND USES THEREFOR CASP4, CA4, ACSL4 ESR1 3303/4885ESR2 4101/4885HDAC1 75/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.